Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease

    NEXT STORY
    Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives & Strategic Plans
    PREV STORY
    Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US

    Today PledPharma (publ) announces that the company has received a positive conclusion of the ...

    author_avatar
    NASDAQ Market News

    ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

    author_avatar
    NASDAQ Market News

    SOTIO to Present at the LifeSci Partners Summer Symposium

    author_avatar
    NASDAQ Market News